Table 1.
Demographic and clinicopathological features of EGFR‐mutated TKI‐treated NSCLC patients enrolled in the study (n = 111)
| Characteristics | n = 111 | Frequencies | |
|---|---|---|---|
| Sex | Male | 47 | 42.3% |
| Female | 64 | 57.7% | |
| Age | Median (SD) | 61.75 (11.48) | |
| ≤63 years | 58 | 52.3% | |
| >63 years | 53 | 47.7% | |
| Self‐reported skin color | White | 96 | 86.5% |
| Other | 15 | 13.5% | |
| Smoking status | Never | 65 | 58.6% |
| Current | 17 | 15.3% | |
| Former | 28 | 25.2% | |
| NA | 1 | 0.9% | |
| ECOG PS | 0–1 | 78 | 70.3% |
| 2 | 20 | 18.0% | |
| 3–4 | 8 | 7.2% | |
| NA | 5 | 4.5% | |
| Weight loss in the last six months prior to diagnosis | >10% | 18 | 16.2% |
| <10% | 46 | 41.4% | |
| None | 39 | 35.1% | |
| NA | 8 | 7.3% | |
| TNM stage | I/II/III | 12 | 10.8% |
| IV | 99 | 89.2% | |
| Histological subtype | Acinar | 42 | 37.8% |
| Mucinous | 1 | 0.9% | |
| Lepidic | 8 | 7.3% | |
| Papillary | 10 | 9.0% | |
| Solid | 10 | 9.0% | |
| Others | 7 | 6.3% | |
| Not defined | 33 | 29.7% | |
| Central nervous system metastasis | Yes | 32 | 28.8% |
| No | 79 | 71.2% | |
| Current status | Alive | 24 | 21.6% |
| Dead due to cancer | 80 | 72.1% | |
| Dead due to comorbidity | 1 | 0.9% | |
| NA | 6 | 5.4% | |
| Response to TKI treatment | Partial response | 78 | 70.3% |
| Stable disease | 18 | 16.2% | |
| Disease progression | 15 | 13.5% | |
| EGFR mutation according to exon location | Exon 19 | 69 | 62.2% |
| Exon 20 | 3 | 2.7% | |
| Exon 21 | 25 | 22.5% | |
| Exon 18 and exon 21 | 2 | 1.8% | |
| Exon 19 and exon 20 | 9 | 8.1% | |
| Exon 20 and exon 21 | 3 | 2.7% |
NA, data unavailable; SD, standard deviation.